226 related articles for article (PubMed ID: 25243340)
21. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
Reisner C; Fabbri LM; Kerwin EM; Fogarty C; Spangenthal S; Rabe KF; Ferguson GT; Martinez FJ; Donohue JF; Darken P; St Rose E; Orevillo C; Strom S; Fischer T; Golden M; Dwivedi S
Respir Res; 2017 Jan; 18(1):8. PubMed ID: 28061907
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
Vincken W; Aumann J; Chen H; Henley M; McBryan D; Goyal P
Int J Chron Obstruct Pulmon Dis; 2014; 9():215-28. PubMed ID: 24596459
[TBL] [Abstract][Full Text] [Related]
23. A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD.
Kerwin EM; Spangenthal S; Kollar C; St Rose E; Reisner C
Respir Res; 2018 Mar; 19(1):38. PubMed ID: 29506504
[TBL] [Abstract][Full Text] [Related]
24. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients.
Vogelmeier C; Verkindre C; Cheung D; Galdiz JB; Güçlü SZ; Spangenthal S; Overend T; Henley M; Mizutani G; Zeldin RK
Pulm Pharmacol Ther; 2010 Oct; 23(5):438-44. PubMed ID: 20416390
[TBL] [Abstract][Full Text] [Related]
25. Effect of background long-acting beta
Kerwin EM; Tosiello R; Price B; Sanjar S; Goodin T
Int J Chron Obstruct Pulmon Dis; 2018; 13():2917-2929. PubMed ID: 30275690
[TBL] [Abstract][Full Text] [Related]
26. A novel model-based approach for dose determination of glycopyrronium bromide in COPD.
Arievich H; Overend T; Renard D; Gibbs M; Alagappan V; Looby M; Banerji D
BMC Pulm Med; 2012 Dec; 12():74. PubMed ID: 23217058
[TBL] [Abstract][Full Text] [Related]
27. Dose-response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT).
Beeh KM; Emirova A; Prunier H; Santoro D; Nandeuil MA
Int J Chron Obstruct Pulmon Dis; 2018; 13():1701-1711. PubMed ID: 29872288
[TBL] [Abstract][Full Text] [Related]
28. A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD.
Maltais F; Ferguson GT; Feldman GJ; Deslee G; Bourdin A; Fjällbrant H; Siwek-Posłuszna A; Jenkins MA; Martin UJ
Adv Ther; 2019 Sep; 36(9):2434-2449. PubMed ID: 31267366
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.
Ferguson GT; Rodriguez-Roisin R; Reisner C; Maes A; Siddiqui S; Martin UJ
Int J Chron Obstruct Pulmon Dis; 2018; 13():945-953. PubMed ID: 29606861
[TBL] [Abstract][Full Text] [Related]
30. A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease.
Pudi KK; Barnes CN; Moran EJ; Haumann B; Kerwin E
Respir Res; 2017 Nov; 18(1):182. PubMed ID: 29096627
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.
Rajagopalan K; Bloudek L; Marvel J; Dembek C; Kavati A
Int J Chron Obstruct Pulmon Dis; 2018; 13():3867-3877. PubMed ID: 30568438
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.
Wang C; Sun T; Huang Y; Humphries M; Bai L; Li L; Wang Q; Kho P; Firth R; D'Andrea P
Int J Chron Obstruct Pulmon Dis; 2015; 10():57-68. PubMed ID: 25609940
[TBL] [Abstract][Full Text] [Related]
33. Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD.
De Backer W; De Backer J; Verlinden I; Leemans G; Van Holsbeke C; Mignot B; Jenkins M; Griffis D; Ivanov S; Fitzpatrick J; St Rose E; Martin UJ; Reisner C
Ther Adv Respir Dis; 2020; 14():1753466620916990. PubMed ID: 32380894
[TBL] [Abstract][Full Text] [Related]
34. Clinically Important Deterioration Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Nebulized Glycopyrrolate: A Post Hoc Analysis of Pooled Data from Two Randomized, Double-Blind, Placebo-Controlled Studies.
Kerwin EM; Murray L; Niu X; Dembek C
Int J Chron Obstruct Pulmon Dis; 2020; 15():2309-2318. PubMed ID: 33061349
[TBL] [Abstract][Full Text] [Related]
35. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T
Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
[TBL] [Abstract][Full Text] [Related]
36. FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.
Mahler DA; Kerwin E; Ayers T; FowlerTaylor A; Maitra S; Thach C; Lloyd M; Patalano F; Banerji D
Am J Respir Crit Care Med; 2015 Nov; 192(9):1068-79. PubMed ID: 26177074
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology.
Ferguson GT; Reisner C; Pearle J; DePetrillo P; Maes A; Martin UJ
Pulm Pharmacol Ther; 2018 Apr; 49():67-74. PubMed ID: 29567116
[TBL] [Abstract][Full Text] [Related]
38. Nebulized glycopyrrolate (Lonhala Magnair) for COPD.
Med Lett Drugs Ther; 2018 Apr; 60(1543):72. PubMed ID: 29667949
[No Abstract] [Full Text] [Related]
39. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
[TBL] [Abstract][Full Text] [Related]
40. Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING).
Marin JM; Beeh KM; Clemens A; Castellani W; Schaper L; Saralaya D; Gunstone A; Casamor R; Kostikas K; Aalamian-Mattheis M
Int J Chron Obstruct Pulmon Dis; 2016; 11():1425-34. PubMed ID: 27418815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
